Eagle Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• Ryanodex and Standard of Care · Anesthesiology / Critical Care
  Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.

Phase 2 pipeline

• CAL02 · Inflammation
  CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.
• Dantrolene sodium for injectable suspension · Musculoskeletal
  Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.

Phase 1 pipeline

• Fulvestrant for Injectable Suspension

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Eagle Pharmaceuticals, Inc. portfolio CI brief
• Eagle Pharmaceuticals, Inc. pipeline updates RSS